Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Dermatology | Family Medicine | Gastroenterology | Internal Medicine | Allergy | Nursing | Pediatrics | Pulmonology | Journal

Back to Journal Articles

C1 Esterase Inhibitor Effective in Hereditary Angioedema

Last Updated: November 03, 2011.

 

Single 20 U/kg dose safe, complete symptom resolution at any body location in 15.5 hrs

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A single dose of 20 U/kg C1 esterase inhibitor concentrate is safe and effective for treatment of successive hereditary angioedema attacks at any body location, according to a study published in the December issue of Allergy.

THURSDAY, Nov. 3 (HealthDay News) -- A single dose of 20 U/kg C1 esterase inhibitor (C1-INH) concentrate is safe and effective for treatment of successive hereditary angioedema (HAE) attacks at any body location, according to a study published in the December issue of Allergy.

Timothy J. Craig, D.O., from Penn State University College of Medicine in Hershey, and colleagues investigated the safety and efficacy of long-term treatment with 20 U/kg C1-INH for 1,085 HAE attacks at any body location in 57 patients (aged 10 to 53 years). Efficacy outcomes were analyzed on a per-patient and per-attack basis, and included patient reported time to onset of symptom relief, and time to complete resolution of all symptoms. Safety was assessed through adverse events, vital signs, viral safety, and anti-C1-INH antibodies. The participants were followed up for a median duration of 24 months.

The investigators found that the median time to onset of symptom relief in the per-patient analysis was 0.46 hours, and was similar for all types of attacks (0.39 to 0.48 hours). The median time to complete resolution of symptoms was 15.5 hours. Efficacy outcomes were not clinically affected by relevant demographic factors, type of HAE, intensity of attacks, time to treatment, use of androgens, and presence of anti-C1-INH antibodies. No patient had treatment-related safety concerns or inhibitory anti-C1-INH antibodies.

"C1-INH concentrate at a single dose of 20 U/kg body weight is safe and provides reliable efficacy for the long-term treatment of successive HAE attacks at any body location," the authors write.

Several authors disclosed financial relationships with pharmaceutical and biotherapeutics companies, including CSL Behring, which funded the study.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: Device Approved to Remedy Abdominal Aneurysms Next: Rectal CA Radiotherapy Tied to Lower Testosterone Levels

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.